Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Cangrelor for the treatment of patients with Arterial Thrombosis.

Publication ,  Journal Article
Tantry, U; Chaudhary, R; Kubica, J; Bliden, K; Gurbel, PA
Published in: Expert Opin Pharmacother
August 2018

All oral P2Y12 receptor blockers are associated with some degree of delayed onset and offset of pharmacodynamic (PD) effects in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Although intravenous glycoprotein IIb/IIIa inhibitors are associated with rapid onset of action, they are also associated with delayed offset and other limitations such as elevated bleeding risk and thrombocytopenia. Areas covered: In this review, the authors focus on cangrelor, an intravenous, reversible P2Y12 receptor blocker with fast onset and offset of effects. The authors also describe the pharmacologic effects of cangrelor and its pharmacologic interaction with other P2Y12 receptor inhibitors. Finally, the authors discuss the large-scale clinical trials that compared the efficacy and safety of cangrelor with clopidogrel. Expert opinion: In ACS patients undergoing PCI, cangrelor is most desirable to effectively prevent periprocedural ischemic events and to avoid excessive bleeding. Indeed, any high-risk patient with ST-segment elevation myocardial infraction or patient who is unable to take oral medications is a potential candidate for intravenous cangrelor therapy. Furthermore, stable patients with coronary artery disease, who are considered for ad hoc PCI following coronary angiography, may be considered for treatment with cangrelor to reduce post-PCI thrombotic events.

Duke Scholars

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

August 2018

Volume

19

Issue

12

Start / End Page

1389 / 1398

Location

England

Related Subject Headings

  • Thrombosis
  • Platelet Aggregation Inhibitors
  • Pharmacology & Pharmacy
  • Humans
  • Adenosine Monophosphate
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tantry, U., Chaudhary, R., Kubica, J., Bliden, K., & Gurbel, P. A. (2018). Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother, 19(12), 1389–1398. https://doi.org/10.1080/14656566.2018.1506767
Tantry, Udaya, Rahul Chaudhary, Jacek Kubica, Kevin Bliden, and Paul A. Gurbel. “Cangrelor for the treatment of patients with Arterial Thrombosis.Expert Opin Pharmacother 19, no. 12 (August 2018): 1389–98. https://doi.org/10.1080/14656566.2018.1506767.
Tantry U, Chaudhary R, Kubica J, Bliden K, Gurbel PA. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2018 Aug;19(12):1389–98.
Tantry, Udaya, et al. “Cangrelor for the treatment of patients with Arterial Thrombosis.Expert Opin Pharmacother, vol. 19, no. 12, Aug. 2018, pp. 1389–98. Pubmed, doi:10.1080/14656566.2018.1506767.
Tantry U, Chaudhary R, Kubica J, Bliden K, Gurbel PA. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2018 Aug;19(12):1389–1398.

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

August 2018

Volume

19

Issue

12

Start / End Page

1389 / 1398

Location

England

Related Subject Headings

  • Thrombosis
  • Platelet Aggregation Inhibitors
  • Pharmacology & Pharmacy
  • Humans
  • Adenosine Monophosphate
  • 1115 Pharmacology and Pharmaceutical Sciences